Cargando…
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
PURPOSE OF REVIEW: Adalimumab is one of the top-selling drugs worldwide. Its imminent patent expiration has seen the emergence of numerous biosimilar agents. In this article, we recap the evidence from bio-originator trials in rheumatoid arthritis (RA) to provide context for a critical review of bio...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097048/ https://www.ncbi.nlm.nih.gov/pubmed/30094742 http://dx.doi.org/10.1007/s11926-018-0769-6 |
_version_ | 1783348225338507264 |
---|---|
author | Zhao, Sizheng Chadwick, Laura Mysler, Eduardo Moots, Robert J. |
author_facet | Zhao, Sizheng Chadwick, Laura Mysler, Eduardo Moots, Robert J. |
author_sort | Zhao, Sizheng |
collection | PubMed |
description | PURPOSE OF REVIEW: Adalimumab is one of the top-selling drugs worldwide. Its imminent patent expiration has seen the emergence of numerous biosimilar agents. In this article, we recap the evidence from bio-originator trials in rheumatoid arthritis (RA) to provide context for a critical review of biosimilar trial data. RECENT FINDINGS: Currently, three adalimumab biosimilars are approved in Europe and/or the USA: Amgen’s ABP 501 (AMJEVITA/Solymbic), Boehringer Ingelheim’s BI 695501 (Cyltezo) and Samsung Bioepis’s SB5 (Imraldi). All three agents met their pre-specified equivalence criteria. Subtle differences in adverse events and clinical responses between the reference and biosimilar products were noted. SUMMARY: The introduction of adalimumab biosimilars will offer exciting opportunities in improving treatment access and increasing treatment options for RA and other licensed indications. Real-world data will further provide assurances on efficacy as well as safety. |
format | Online Article Text |
id | pubmed-6097048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-60970482018-08-24 Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis Zhao, Sizheng Chadwick, Laura Mysler, Eduardo Moots, Robert J. Curr Rheumatol Rep Biosimilars (E Mysler, Section Editor) PURPOSE OF REVIEW: Adalimumab is one of the top-selling drugs worldwide. Its imminent patent expiration has seen the emergence of numerous biosimilar agents. In this article, we recap the evidence from bio-originator trials in rheumatoid arthritis (RA) to provide context for a critical review of biosimilar trial data. RECENT FINDINGS: Currently, three adalimumab biosimilars are approved in Europe and/or the USA: Amgen’s ABP 501 (AMJEVITA/Solymbic), Boehringer Ingelheim’s BI 695501 (Cyltezo) and Samsung Bioepis’s SB5 (Imraldi). All three agents met their pre-specified equivalence criteria. Subtle differences in adverse events and clinical responses between the reference and biosimilar products were noted. SUMMARY: The introduction of adalimumab biosimilars will offer exciting opportunities in improving treatment access and increasing treatment options for RA and other licensed indications. Real-world data will further provide assurances on efficacy as well as safety. Springer US 2018-08-09 2018 /pmc/articles/PMC6097048/ /pubmed/30094742 http://dx.doi.org/10.1007/s11926-018-0769-6 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Biosimilars (E Mysler, Section Editor) Zhao, Sizheng Chadwick, Laura Mysler, Eduardo Moots, Robert J. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis |
title | Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis |
title_full | Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis |
title_fullStr | Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis |
title_full_unstemmed | Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis |
title_short | Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis |
title_sort | review of biosimilar trials and data on adalimumab in rheumatoid arthritis |
topic | Biosimilars (E Mysler, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097048/ https://www.ncbi.nlm.nih.gov/pubmed/30094742 http://dx.doi.org/10.1007/s11926-018-0769-6 |
work_keys_str_mv | AT zhaosizheng reviewofbiosimilartrialsanddataonadalimumabinrheumatoidarthritis AT chadwicklaura reviewofbiosimilartrialsanddataonadalimumabinrheumatoidarthritis AT myslereduardo reviewofbiosimilartrialsanddataonadalimumabinrheumatoidarthritis AT mootsrobertj reviewofbiosimilartrialsanddataonadalimumabinrheumatoidarthritis |